Abstract
Clinical activity of tazemetostat, an EZH2 inhibitor, among patients with advanced endometrioid endometrial cancer and ovarian clear cell carcinoma with and without ARID1A mutations (NRG-GY014)
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have